Animal Defense

Vivisection is a Sham

Canada Gosling

Essays

The wonders of "scientific" medicine.

PROZAC: Very Depressing!

DeKalb, Illinois - February 14, 2008: 27-year-old Steven Kazmierczak shot and killed five people and wounded 16 others before killing himself in a Northern Illinois University auditorium. According to his girlfriend, he had recently been taking Prozac, Xanax and Ambien. Toxicology reports showed that he still had trace amounts of Xanax in his system.

Omaha, Nebraska - December 5, 2007: 19-year-old Robert Hawkins killed eight people and wounded five before committing suicide in an Omaha mall. Hawkins’ friend told CNN that the gunman was on antidepressants, and autopsy results confirmed he was under the influence of the “anti-anxiety” drug Valium.

Jokela, Finland - November 7, 2007: 18-year-old Finnish gunman Pekka-Eric Auvinen had been taking antidepressants before he killed eight people and wounded a dozen more at Jokela High School in southern Finland, then committed suicide.

Cleveland, Ohio - October 10, 2007: 14-year-old Asa Coon stormed through his school with a gun in each hand, shooting and wounding four before taking his own life. court records show Coon had been placed on the antidepressant Trazadone.

Blacksburg, Virginia - April 16, 2007: The psychiatric drug history of Seung-Hui Cho in the Virginia Tech Massacre was never made public. Initial reports stated that “depression medication” was found among Cho’s belongings. But neither his toxicology reports, nor his recent medical history were ever released to find out whether Cho had been in withdrawal from psychiatric medication. (33 were killed and 29 injured, but this was not included in the total of dead and wounded cited above.)

Red Lake Indian Reservation, Minnesota - March 21, 2005: 16-year-old Native American Jeff Weise, reportedly under the influence of the antidepressant Prozac, went on a shooting rampage at home and at his school, killing nine people and wounding five before committing suicide. 

Greenbush, New York - February 2004: 16-year-old Jon Romano strolled into his high school in east Greenbush and opened fire with a shotgun. Special education teacher Michael Bennett was hit in the leg. Romano had been taking “medication for depression.” 

El Cajon, California - March 22, 2001: 18-year-old Jason Hoffman was on two antidepressants, Effexor and Celexa, when he opened fire at his California high school wounding five. Hoffman had also undergone an “anger management” program.

Williamsport, Pennsylvania - March 7, 2000: 14-year-old Elizabeth Bush was on the antidepressant Prozac when she blasted away at fellow students in Williamsport, Pennsylvania, wounding one.

Conyers, Georgia - May 20, 1999: 15-year-old T.J. Solomon was being treated with a mix of antidepressants when he opened fire on and wounded 6 of his classmates.

Columbine, Colorado - April 20, 1999: 18-year-old Eric Harris was on the antidepressant Luvox when he and his partner Dylan Klebold killed 12 classmates and a teacher and wounded 23 others before taking their own lives in the bloodiest school massacre in history. The coroner confirmed that the antidepressant was in his system through toxicology reports while Dylan Klebold’s autopsy was never made public. Harris and Klebold underwent “anger management” and “death education” classes.

Notus, Idaho - April 16, 1999: 15-year-old Shawn Cooper fired two shotgun rounds in his school narrowly missing students; he was taking a mix of antidepressants.

Springfield, Oregon - May 21, 1998: 15-year-old Kip Kinkel murdered his own parents and then proceeded to school where he opened fire on students in the cafeteria, killing two and wounding 22. Kinkel had been on Prozac. Kinkel also underwent “anger management” classes.

Research related links
  1. NIU Shooter On a “Cocktail” of Dangerous Pharam Drugs
  2. University Police: Illinois Campus Shooter On “Medication”
  3. German Shooter Avid Violent Video Game Player
  4. Coincidence? German school gunman kills 17 after Alabama shooting
  5. NIU Shooter Bought Glock Clips, Holster Online
  6. NIU Shooting Rekindles Debate over Prozac and Violence
  7. Woman Kills Two Students, Self at US College
  8. Journalists targeted in latest Mexico drug violence
  9. China’s Organ Harvesting Confirmed By a Former Detention Center Prisoner
  10. NIU shooter did stint in mental health center
  11. America’s Medicated Army
  12. Congress: Drug Mothers Suffering from Postpartum Depression
"Science based medicine" depends on Big Pharma's faith no one will be caught...

Judging by the fraudulent studies and ghost written articles planted in "prestigious medical journals" by the pharmaceutical companies it would seem science based evidence has more to do with faith based hope that the fraud will just keep on going like the Energizer Rabbit and no one will get tripped up.

If one doctor can literally fabricate a whopping twenty-one studies and have them all rubber-stamped by his colleagues, his peers and the medical journals, then have them approved by government regulatory agencies such as Health Canada and it United States counterpart - what does this say about the credibility of the whole system? For medical doctors and their professional association or licensing board to now claim anything resembling "science based medicine," they should have to audit every single study published in every single medical journal or co-authored by every single researcher who had anything at all to do with Dr. Reuben.

"State Sues Maker Of Risperdal: New Mexico's AG Claims Dangers Of Antipsychotic Hidden"

-TradingMarkets.com 09/15/2008- Risperdal is a wildly successful antipsychotic drug that has made millions for the Johnson and Johnson subsidiary that developed and marketed it.

But the New Mexico Attorney General's Office contends that the manufacturer, Janssen, a division of Ortho-McNeil-Janssen Pharmaceutical Inc., hid the dangers of the product and marketed it to populations for which it was never intended -- particularly the elderly and children.

The state claims the company's alleged promotion of the drug for nonmedically necessary uses cost New Mexico taxpayers millions of dollars out of the Medicaid program to reimburse patients who were prescribed Risperdal. And it also claims a host of state laws were broken in the process, including the Unfair Practices Act.

Janssen spokeswoman Kara Russell said the company is committed to the highest ethical standards and responsible behavior. She said Janssen routinely informs and discloses all appropriate

The company promotes its drugs only for uses approved by the U.S. Food and Drug Administration, she said. For Risperdal, those are bipolar mania, schizophrenia and the irritability associated with autistic disorder.

"We only promote our products for the indications for which they are approved," Russell said.

According to the lawsuit:

Janssen got FDA approval to market Risperdal oral tablets for the treatment of schizophrenia in 1993 and for variations to treat bipolar disorder in 2003. But the drug has shown a propensity for its users to gain weight, have movement disorders and other health problems, including diabetes.

 
Since its launch, the maker has "engaged in widespread fraudulent statements and conduct, and pervasive false and misleading marketing, advertising and promotion." The maker failed to warn and misled physicians, consumers and the state regarding its adverse effects.
 
The maker actively marketed the drug for uses in several populations where its safety had not been established, such as people with sleep disorders, elderly patients with dementia and patients with depressive or mood disorders.
 
The alleged scheme was carried out by directly soliciting physicians to prescribe it by giving false information to them and to pharmacists, including the development of deceptive and misleading medical literature and funding of questionable scientific literature.
 
One marketing plan used company-funded events at which doctors selected, trained and approved by Janssen would falsely oversell Risperdal's safety and effectiveness, according to the complaint.
 
The strategy worked, making more than two-thirds of all dollars spent on Risperdal going for nonmedically necessary uses and making the drug the mostly widely used antipsychotic of its type in the world, with sales skyrocketing to $3.5 billion in 2005.
 
The lawsuit was filed for the Attorney General's Office in the 1st Judicial District Court in Santa Fe by a Houston civil litigation firm, Bailey Perrin Bailey, which specializes in lawsuits over the new generation of antipsychotic drugs known as atypical antipsychotics.
The firm represents other states in lawsuits over Risperdal, including one filed in Pennsylvania state court in February.

Examples of Fraudulent Science Based Medicine: A list of Medical studies authored / fabricated by the shamed Dr. Scott Reuben

Preventing the development of chronic pain after thoracic surgery.
Reuben SS, Yalavarthy L.
J Cardiothorac Vasc Anesth. 2008 Dec;22(6):890-903. Epub 2008 May 7. No abstract available.
PMID: 18834790

A prospective randomized trial on the role of perioperative celecoxib administration for total knee arthroplasty: improving clinical outcomes.
Reuben SS, Buvenandran A, Katz B, Kroin JS.
Anesth Analg. 2008 Apr;106(4):1258-64, table of contents.
PMID: 18349203

Update on the role of nonsteroidal anti-inflammatory drugs and coxibs in the management of acute pain.
Reuben SS.
Curr Opin Anaesthesiol. 2007 Oct;20(5):440-50. Review.
PMID: 17873597

The effect of initiating a preventive multimodal analgesic regimen on long-term patient outcomes for outpatient anterior cruciate ligament reconstruction surgery.
Reuben SS, Ekman EF.
Anesth Analg. 2007 Jul;105(1):228-32.
PMID: 17578979

Evaluating the analgesic efficacy of administering celecoxib as a component of multimodal analgesia for outpatient anterior cruciate ligament reconstruction surgery.
Reuben SS, Ekman EF, Charron D.
Anesth Analg. 2007 Jul;105(1):222-7.
PMID: 17578978

Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques.
Reuben SS, Buvanendran A.
J Bone Joint Surg Am. 2007 Jun;89(6):1343-58. Review.
PMID: 17545440

The efficacy of postoperative perineural infusion of bupivacaine and clonidine after lower extremity amputation in preventing phantom limb and stump pain.
Madabhushi L, Reuben SS, Steinberg RB, Adesioye J.
J Clin Anesth. 2007 May;19(3):226-9.
PMID: 17531734

Chronic pain after surgery: what can we do to prevent it.
Reuben SS.
Curr Pain Headache Rep. 2007 Feb;11(1):5-13. Review.
PMID: 17214915

The analgesic efficacy of celecoxib, pregabalin, and their combination for spinal fusion surgery.
Reuben SS, Buvanendran A, Kroin JS, Raghunathan K.
Anesth Analg. 2006 Nov;103(5):1271-7.
PMID: 17056968

Acute post-surgical pain management: a critical appraisal of current practice, December 2-4, 2005.
Rathmell JP, Wu CL, Sinatra RS, Ballantyne JC, Ginsberg B, Gordon DB, Liu SS, Perkins FM, Reuben SS, Rosenquist RW, Viscusi ER.
Reg Anesth Pain Med. 2006 Jul-Aug;31(4 Suppl 1):1-42.
PMID: 16849098

Postoperative modulation of central nervous system prostaglandin E2 by cyclooxygenase inhibitors after vascular surgery.
Reuben SS, Buvanendran A, Kroin JS, Steinberg RB.
Anesthesiology. 2006 Mar;104(3):411-6.
PMID: 16508386

The incidence of complex regional pain syndrome after fasciectomy for Dupuytren's contracture: a prospective observational study of four anesthetic techniques.
Reuben SS, Pristas R, Dixon D, Faruqi S, Madabhushi L, Wenner S.
Anesth Analg. 2006 Feb;102(2):499-503.
PMID: 16428550

EF, Raghunathan K, Steinberg RB, Blinder JL, Adesioye J.
Reg Anesth Pain Med. 2006 Jan-Feb;31(1):6-13.
PMID: 16418018

Interscalene block superior to general anesthesia.
Reuben SS.
Anesthesiology. 2006 Jan;104(1):207; author reply 208-9. No abstract available.
PMID: 16394719

High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion.
Reuben SS, Ablett D, Kaye R.
Can J Anaesth. 2005 May;52(5):506-12.
PMID: 15872130

More on current issues in pain management for the primary care practitioner. Acute pain: a multi-modal management approach.
Carr DB, Reuben S.
J Pain Palliat Care Pharmacother. 2005;19(1):69-70. No abstract available.
PMID: 15814519

The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion.
Reuben SS, Ekman EF.
J Bone Joint Surg Am. 2005 Mar;87(3):536-42.
PMID: 15741619

The prevention of post-surgical neuralgia.
Reuben SS.
Pain. 2005 Jan;113(1-2):242-3; author reply 243-4. No abstract available.
PMID: 15621388

Surgery on the affected upper extremity of patients with a history of complex regional pain syndrome: the use of intravenous regional anesthesia with clonidine.
Reuben SS, Rosenthal EA, Steinberg RB, Faruqi S, Kilaru PA.
J Clin Anesth. 2004 Nov;16(7):517-22.
PMID: 15590255

Preventing the development of complex regional pain syndrome after surgery.
Reuben SS.
Anesthesiology. 2004 Nov;101(5):1215-24. Review. No abstract available.
PMID: 15505459

Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome.
Reuben SS, Makari-Judson G, Lurie SD.
J Pain Symptom Manage. 2004 Feb;27(2):133-9.
PMID: 15157037

Analgesic effect of clonidine added to bupivacaine 0.125% in paediatric caudal blockade.
Joshi W, Connelly NR, Freeman K, Reuben SS.
Paediatr Anaesth. 2004 Jun;14(6):483-6.
PMID: 15153211

The perioperative use of cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs may offer a safer alternative.
Reuben SS, Connelly NR.
Anesthesiology. 2004 Mar;100(3):748. No abstract available.
PMID: 15109000

An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management.
Joshi W, Connelly NR, Reuben SS, Wolckenhaar M, Thakkar N.
Anesth Analg. 2003 Jul;97(1):35-8, table of contents.
PMID: 12818939

 
An evaluation of the analgesic efficacy of intravenous regional anesthesia with lidocaine and ketorolac using a forearm versus upper arm tourniquet.
Reuben SS, Steinberg RB, Maciolek H, Manikantan P.
Anesth Analg. 2002 Aug;95(2):457-60, table of contents.
PMID: 12145071

Preoperative administration of controlled-release oxycodone for the management of pain after ambulatory laparoscopic tubal ligation surgery.
Reuben SS, Steinberg RB, Maciolek H, Joshi W.
J Clin Anesth. 2002 May;14(3):223-7.
PMID: 12031758

Intravenous regional anesthesia with clonidine in the management of complex regional pain syndrome of the knee.
Reuben SS, Sklar J.
J Clin Anesth. 2002 Mar;14(2):87-91.
PMID: 11943518

Preemptive multimodal analgesia for anterior cruciate ligament surgery.
Reuben SS, Sklar J.
Reg Anesth Pain Med. 2002 Mar-Apr;27(2):225; author reply 225-6. No abstract available.
PMID: 11915075

Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty.
Reuben SS, Fingeroth R, Krushell R, Maciolek H.
J Arthroplasty. 2002 Jan;17(1):26-31.
PMID: 11805921

The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery.
Reuben SS, Bhopatkar S, Maciolek H, Joshi W, Sklar J.
Anesth Analg. 2002 Jan;94(1):55-9, table of contents.
PMID: 11772800